HomeCompareLGNDV vs JEPQ

LGNDV vs JEPQ: Dividend Comparison 2026

LGNDV yields 4.00% · JEPQ yields 11.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JEPQ wins by $18.8K in total portfolio value
10 years
LGNDV
LGNDV
● Live price
4.00%
Share price
$50.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.9K
Annual income
$517.11
Full LGNDV calculator →
JEPQ
JPMorgan Nasdaq Equity Premium Income ETF
● Live price
11.10%
Share price
$55.52
Annual div
$6.16
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.8K
Annual income
$2,152.59
Full JEPQ calculator →

Portfolio growth — LGNDV vs JEPQ

📍 JEPQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLGNDVJEPQ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LGNDV + JEPQ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LGNDV pays
JEPQ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LGNDV
Annual income on $10K today (after 15% tax)
$340.00/yr
After 10yr DRIP, annual income (after tax)
$439.54/yr
JEPQ
Annual income on $10K today (after 15% tax)
$943.83/yr
After 10yr DRIP, annual income (after tax)
$1,829.70/yr
At 15% tax rate, JEPQ beats the other by $1,390.16/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LGNDV + JEPQ for your $10,000?

LGNDV: 50%JEPQ: 50%
100% JEPQ50/50100% LGNDV
Portfolio after 10yr
$35.4K
Annual income
$1,334.85/yr
Blended yield
3.77%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LGNDV buys
0
JEPQ buys
0
No recent congressional trades found for LGNDV or JEPQ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLGNDVJEPQ
Forward yield4.00%11.10%
Annual dividend / share$2.00$6.16
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$25.9K$44.8K
Annual income after 10y$517.11$2,152.59
Total dividends collected$4.6K$16.3K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: LGNDV vs JEPQ ($10,000, DRIP)

YearLGNDV PortfolioLGNDV Income/yrJEPQ PortfolioJEPQ Income/yrGap
1← crossover$11,100$400.00$11,930$1,110.39$830.00JEPQ
2$12,292$414.95$14,133$1,224.34$1.8KJEPQ
3$13,582$429.45$16,632$1,340.46$3.0KJEPQ
4$14,976$443.47$19,454$1,457.97$4.5KJEPQ
5$16,481$457.01$22,626$1,576.08$6.1KJEPQ
6$18,105$470.04$26,175$1,694.09$8.1KJEPQ
7$19,855$482.57$30,133$1,811.32$10.3KJEPQ
8$21,739$494.59$34,531$1,927.17$12.8KJEPQ
9$23,767$506.10$39,403$2,041.08$15.6KJEPQ
10$25,948$517.11$44,787$2,152.59$18.8KJEPQ

LGNDV vs JEPQ: Complete Analysis 2026

LGNDVStock

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is based in San Diego, California.

Full LGNDV Calculator →

JEPQETF

The fund seeks to achieve this objective by (1) creating an actively managed portfolio of equity securities comprised significantly of those included in the fund’s primary benchmark, the Nasdaq-100 Index (the Benchmark), and (2) through equity-linked notes (ELNs), selling call options with exposure to the Benchmark. It is non-diversified.

Full JEPQ Calculator →
📬

Get this LGNDV vs JEPQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LGNDV vs SCHDLGNDV vs JEPILGNDV vs OLGNDV vs KOLGNDV vs MAINLGNDV vs XYLDLGNDV vs QYLDLGNDV vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.